These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28906003)

  • 1. Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection.
    Trivedi S; Miao C; Al-Abdallat MM; Haddadin A; Alqasrawi S; Iblan I; Nsour MA; Alsanouri T; Ali SS; Rha B; Gerber SI; Payne DC; Tamin A; Thornburg NJ
    J Med Virol; 2018 Feb; 90(2):367-371. PubMed ID: 28906003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and preliminary validation of a MERS-CoV ELISA for serological testing of camels and alpacas.
    McNabb L; Durr PA; Lunt R; Barr J; Adams TE; Pearce L; Poon LLM; Perera RAM; Demissie GF; Bowden TR
    J Virol Methods; 2024 Jun; 327():114923. PubMed ID: 38561124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus.
    Lee K; Ko HL; Lee EY; Park HJ; Kim YS; Kim YS; Cho NH; Park MS; Lee SM; Kim J; Kim H; Seong BL; Nam JH
    Microbiol Immunol; 2018 Sep; 62(9):574-584. PubMed ID: 30117617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests.
    Ko JH; Müller MA; Seok H; Park GE; Lee JY; Cho SY; Ha YE; Baek JY; Kim SH; Kang JM; Kim YJ; Jo IJ; Chung CR; Hahn MJ; Drosten C; Kang CI; Chung DR; Song JH; Kang ES; Peck KR
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2179-2186. PubMed ID: 28695355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.
    Al-Amri SS; Hashem AM
    Methods Mol Biol; 2020; 2099():127-133. PubMed ID: 31883093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies.
    Okba NMA; Widjaja I; Li W; GeurtsvanKessel CH; Farag EABA; Al-Hajri M; Park WB; Oh MD; Reusken CBEM; Koopmans MPG; Bosch BJ; Haagmans BL
    Emerg Infect Dis; 2020 May; 26(5):1024-1027. PubMed ID: 32150528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive ELISA for the Detection of Serum Antibodies Specific for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
    Fukushi S
    Methods Mol Biol; 2020; 2203():55-65. PubMed ID: 32833203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients.
    Algaissi A; Alfaleh MA; Hala S; Abujamel TS; Alamri SS; Almahboub SA; Alluhaybi KA; Hobani HI; Alsulaiman RM; AlHarbi RH; ElAssouli MA; Alhabbab RY; AlSaieedi AA; Abdulaal WH; Al-Somali AA; Alofi FS; Khogeer AA; Alkayyal AA; Mahmoud AB; Almontashiri NAM; Pain A; Hashem AM
    Sci Rep; 2020 Oct; 10(1):16561. PubMed ID: 33024213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Middle East Respiratory Syndrome Coronavirus Antibodies in Bactrian and Hybrid Camels from Dubai.
    Lau SKP; Li KSM; Luk HKH; He Z; Teng JLL; Yuen KY; Wernery U; Woo PCY
    mSphere; 2020 Jan; 5(1):. PubMed ID: 31969478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus.
    Harvey R; Mattiuzzo G; Hassall M; Sieberg A; Müller MA; Drosten C; Rigsby P; Oxenford CJ;
    Emerg Infect Dis; 2019 Oct; 25(10):1878-1883. PubMed ID: 31423969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.
    Fukushi S; Fukuma A; Kurosu T; Watanabe S; Shimojima M; Shirato K; Iwata-Yoshikawa N; Nagata N; Ohnishi K; Ato M; Melaku SK; Sentsui H; Saijo M
    J Virol Methods; 2018 Jan; 251():22-29. PubMed ID: 28993122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of different indirect ELISAs for MERS-CoV serological testing.
    Hashem AM; Al-Amri SS; Al-Subhi TL; Siddiq LA; Hassan AM; Alawi MM; Alhabbab RY; Hindawi SI; Mohammed OB; Amor NS; Alagaili AN; Mirza AA; Azhar EI
    J Immunol Methods; 2019 Mar; 466():41-46. PubMed ID: 30659836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
    Wang W; Wang H; Deng Y; Song T; Lan J; Wu G; Ke C; Tan W
    Emerg Microbes Infect; 2016 Nov; 5(11):e113. PubMed ID: 27826140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East respiratory syndrome corona virus.
    Abbas AT; El-Kafrawy SA; Tabll AA; Hashem AM; Al Subhi TL; Alsaadi M; Azhar EI
    Hum Antibodies; 2024; 32(3):129-137. PubMed ID: 38758996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.
    Agnihothram S; Gopal R; Yount BL; Donaldson EF; Menachery VD; Graham RL; Scobey TD; Gralinski LE; Denison MR; Zambon M; Baric RS
    J Infect Dis; 2014 Apr; 209(7):995-1006. PubMed ID: 24253287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection.
    Park SW; Perera RA; Choe PG; Lau EH; Choi SJ; Chun JY; Oh HS; Song KH; Bang JH; Kim ES; Kim HB; Park WB; Kim NJ; Poon LL; Peiris M; Oh MD
    Euro Surveill; 2015; 20(41):. PubMed ID: 26538277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sero-prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) specific antibodies in dromedary camels in Tabuk, Saudi Arabia.
    Harrath R; Abu Duhier FM
    J Med Virol; 2018 Aug; 90(8):1285-1289. PubMed ID: 29663439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections.
    Okba NMA; Raj VS; Widjaja I; GeurtsvanKessel CH; de Bruin E; Chandler FD; Park WB; Kim NJ; Farag EABA; Al-Hajri M; Bosch BJ; Oh MD; Koopmans MPG; Reusken CBEM; Haagmans BL
    Emerg Infect Dis; 2019 Oct; 25(10):1868-1877. PubMed ID: 31423970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
    Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
    Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.